| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d48f8c03b846acfb609b826f1a9f3e9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-08 |
| filingDate |
1988-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1990-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc7f2631b9a1870a0225a4d16db6b706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85f457eca383c126b0ce861ea6e5e7e8 |
| publicationDate |
1990-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-4950755-A |
| titleOfInvention |
Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane |
| abstract |
Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane of the formula: <IMAGE> wherein R is CH3, R' is <IMAGE> and the process for the synthesis thereof is provided. The compound of the present invention is water soluble, may be administered by intravenous injection and lessens the severity of doxorubicin-induced cardiotoxicity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6531499-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5866570-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005070467-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6294694-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7314862-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003181371-A1 |
| priorityDate |
1985-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |